Prodrug Micelle-Based Nanomedicine for Cancer Treatment

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

This work was supported by the Singapore–China Cooperative Research Project between the Agency of Science, Technology and Research (A*STAR), Singapore and Chinese Ministry of Science and Technology (MOST; R-398-000-077-305; Principal Investigator: S-S Feng), and the NUS FSF grant R-397-000-136-731 and FRC grant R-397-000-136-112; Co-Principal Investigator: S-S Feng). J Zhao and Y Mi are grateful to the National University of Singapore for the financial support for their PhD program. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This work was supported by the Singapore–China Cooperative Research Project between the Agency of Science, Technology and Research (A*STAR), Singapore and Chinese Ministry of Science and Technology (MOST; R-398-000-077-305; Principal Investigator: S-S Feng), and the NUS FSF grant R-397-000-136-731 and FRC grant R-397-000-136-112; Co-Principal Investigator: S-S Feng). J Zhao and Y Mi are grateful to the National University of Singapore for the financial support for their PhD program. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.